InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
willlbone Free
01/31/24 2:48 PM
profile icon
JDCruz Free
11/02/23 9:47 AM
Bullish
Bullish
profile icon
JDCruz Free
10/30/23 11:59 AM
profile icon
retired early Free
06/02/23 3:53 PM
profile icon
Nathan123456 Free
12/22/22 5:32 PM
profile icon
retired early Free
12/22/22 9:35 AM
profile icon
BEIJING BILL Free
08/17/22 12:51 PM
profile icon
retired early Free
05/27/22 1:06 PM
profile icon
THEMASTERS_SON Free
04/04/22 2:56 PM
profile icon
unpathedhaunt Free
03/22/22 11:00 AM
profile icon
retired early Free
02/25/22 12:20 PM
profile icon
retired early Free
01/04/22 2:11 PM
profile icon
Nathans123 Free
01/03/22 8:14 PM
profile icon
shurtha2000 Free
12/20/21 10:50 AM
profile icon
alisher Free
12/20/21 8:46 AM
profile icon
alisher Free
12/04/21 5:48 PM
profile icon
Renegade Rich Free
12/01/21 11:59 AM
profile icon
Mountainman5 Free
09/12/21 8:27 AM
profile icon
retired early Free
08/30/21 10:01 AM
profile icon
retired early Free
08/06/21 1:28 PM
profile icon
oakrock Free
07/28/21 6:37 PM
profile icon
Lowhndcpr Free
07/28/21 9:02 AM
profile icon
shurtha2000 Free
07/27/21 11:07 AM
profile icon
MADDSTACKER Free
07/27/21 10:57 AM
profile icon
retired early Free
07/27/21 9:36 AM
profile icon
bigbut Free
07/27/21 8:19 AM
profile icon
Lowhndcpr Free
07/19/21 4:05 PM
profile icon
420man Free
06/07/21 6:48 PM
profile icon
ClayTrader Free
04/23/21 6:38 PM
profile icon
retired early Free
04/23/21 12:14 PM
profile icon
trendzone Free
04/09/21 1:45 PM
profile icon
DMOST Free
04/09/21 4:07 AM
profile icon
Golden Cross PremiumMember
04/06/21 8:53 PM
profile icon
geocam PremiumMember
03/30/21 4:40 PM
profile icon
DMOST Free
03/25/21 6:17 AM
profile icon
trendzone Free
03/24/21 5:54 PM
profile icon
DMOST Free
03/10/21 7:15 AM
profile icon
ClayTrader Free
03/09/21 4:57 PM
profile icon
retired early Free
03/09/21 1:11 PM
profile icon
Condors rugby Free
03/09/21 11:37 AM
profile icon
trendzone Free
03/09/21 10:49 AM

Oragenics Inc (OGEN) RSS Feed

Followers
75
Posters
198
Posts (Today)
0
Posts (Total)
832
Created
01/29/13
Type
Free
Moderators

 

ORAGENICS - NYSE Market

https://www.oragenics.com/

""Oragenics is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. In addition, Oragenics, Inc. has established an exclusive worldwide channel collaboration with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria.""

https://www.oragenics.com/about

 

Management Team

Alan Joslyn, Ph.D.

President and Chief Executive Officer

Dr. Joslyn was a partner in Lazarus Pharmaceuticals. Prior to that he served as the Chief Executive Officer and Director of several privately held companies including Edusa Pharmaceuticals and Sentinella Pharmaceuticals and prior to that he was the Senior Vice-President Research and Development of Penwest Pharmaceuticals and also held senior drug development positions with Johnson & Johnson.

Michael Sullivan

Chief Financial Officer

Mr. Sullivan has served as our interim principal executive officer since October 30, 2014 and served as our Chief Financial Officer, Secretary and Treasurer since February 6, 2012. Mr. Sullivan has held senior level financial positions for several publicly and privately held businesses including Utek Corporation, eANGLER, and HSN Direct International Limited. Most recently, he was the Group Financial Officer for the Investigative Services and Litigation Consulting Services segment of First Advantage Corporation. Mr. Sullivan is a Florida Certified Public Accountant. He graduated from the Florida State University with a Bachelor of Science in Accounting and a Master of Business Administration.

Dr. Martin Handfield

Senior Vice President of Discovery Research

Dr. Handfield is, the Company’s Senior Vice President of Discovery Research and previously has served as our Director of Research and Development. Prior to joining our Company, Dr. Handfield held a position as Tenured Associate Professor at the Center for Molecular Microbiology and the Department of Oral Biology at the University of Florida College of Dentistry, where he co-invented IVIAT and co-founded ivi Gene Corp. and Epicure Corp. to commercialize this and related technologies. Dr. Handfield holds a B.S. degree in Biochemistry, and a MS degree and PhD in Microbiology and Immunology from the Université Laval College of Medicine in Canada, and did postdoctoral training at the University of Florida.

https://www.oragenics.com/about/management-team


--------------------------------------------------------------------------------------------------------------------------------------------
 
OTC - NEWS
 
http://Oragenics enters into material transfer agreement for COVID-19 vaccine adjuvantSeeking Alpha | 01/07/2021

http://Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies for COVID-19 Vaccine AdjuvantBUSINESS WIRE | 01/07/2021

http://Oragenics, Inc. Announces $6.5 Million Registered Direct OfferingBUSINESS WIRE | 12/24/2020

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OTC - Disclosure's
https://www.otcmarkets.com/stock/OGEN/disclosure

-------------------------------------------------------------------------------------------------------------------------------------------------------------------

Companies News
http://Oragenics working on treatment for oral mucositis with promising AG013 product December 12, 2019

http://Oragenics making 'great progress' enrolling patients in oral mucositis clinical trial October 23, 2019

http://Oragenics, Inc. using Genetically Modified Lactococcus Bacteria found in Yogurt and Milk to create Lantibiotics and Prevent Oral Mucositis May 13, 2019

http://Biotech Outlook 2019: Will the Pressure Continue? December 19, 2018

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

Press Releases

Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine

August 20, 2020
 

See this link to read above Press Release or see more - https://www.oragenics.com/news-media/press-releases

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

Publications

 
Molecular mechanisms of pore formation and membrane disruption by the antimicrobial lantibiotic peptide Mutacin 1140
Preclinical evaluation of the maximum tolerated dose and toxicokinetics of enteric-coated lantibiotic OG253 capsules
Pharmacological, Toxicological, and Dose Range Assessment of OG716, a Novel Lantibiotic for the Treatment of <em>Clostridium difficile</em>-Associated Infection
<i>Chemical Biology & Drug Design</i> Cover Image
Blueprints for the rational design of therapeutic mutacin 1140 variants
OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections
Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection
Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140
Pharmacokinetic and Pharmacodynamic Evaluation of the Lantibiotic MU1140
Development and validation of a LC–MS quantification method for the lantibiotic MU1140 in rat plasma



 

See this link to read above publications - https://www.oragenics.com/news-media/publications


 

 




 

 

See this link to read above publications - https://www.oragenics.com/news-media/publications?page=2

 

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

 

Abstracts

Engineering Improved Variants of Mutacin 1140 by Saturation Mutagenesis
Development of OG716, a Novel Lantibiotic Against Clostridium difficile
 

 




 

See this link to read above Abstracts - https://www.oragenics.com/news-media/abstracts

----------------------------------------------------------------------------------------------------------------------------------------------------------
Share Structure
A/S
  

O/S    51,244,130  01/07/2020

Restricted 

Unrestricted 

Held at DTC 

Float 

Most Liked Posts
(Last 30 Days)
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Most Liked Posts
(Last 30 Days)
New Post